From: Long-term health related quality of life in total knee arthroplasty
Factors | Change in WOMAC exceeding MCID* | |||||
---|---|---|---|---|---|---|
Pain | Stiffness | Function | ||||
Odds ratio** (95% CI) | p value | Odds ratio (95% CI) | p value | Odds ratio (95% CI) | p value | |
Age (as continuous) | 1 (0.97–1.04) | 0.849 | 0.99 (0.96–1.03) | 0.608 | 0.95 (0.92–0.98) | 0.003 |
Age categorized | ||||||
≤ 65 | -ref- | -ref- | -ref- | -ref- | -ref- | -ref- |
65–75 | 1.06 (0.62–1.80) | 0.842 | 1.20 (0.68–2.11) | 0.525 | 0.77 (0.47–1.28) | 0.318 |
≥ 75 | 1.82 (0.92–3.64) | 0.088 | 1.28 (0.62–2.63) | 0.500 | 0.60 (0.31–1.15) | 0.125 |
Gender | ||||||
Female | -ref- | -ref- | -ref- | -ref- | -ref- | -ref- |
Male | 1.06 (0.66–1.71) | 0.810 | 0.82 (0.48–1.38) | 0.446 | 1.60 (1-2.54) | 0.048 |
BMI (as continuous) | 0.93 (0.88–0.98) | 0.004 | 0.93 (0.88–0.98) | 0.009 | 0.93 (0.89–0.98) | 0.006 |
BMI categorized | ||||||
BMI < 25 | -ref- | -ref- | -ref- | -ref- | -ref- | -ref- |
25 ≤ BMI < 30 | 0.61 (0.25–1.47) | 0.271 | 0.48 (0.20–1.14) | 0.098 | 0.59 (0.27–1.28) | 0.184 |
30 ≤ BMI < 35 | 0.35 (0.14–0.86) | 0.022 | 0.40 (0.17–0.95) | 0.038 | 0.46 (0.21–1.02) | 0.055 |
BMI ≥ 35 | 0.39 (0.14–1.06) | 0.065 | 0.29 (0.11–0.81) | 0.018 | 0.27 (0.11–0.69) | 0.006 |
Social support | 1.17 (0.61–2.25) | 0.631 | 1.67 (0.81–3.42) | 0.164 | 1.08 (0.57–2.06) | 0.809 |
Civil status categorized | ||||||
Married or Partner | 0.60 (0.38–0.95) | 0.028 | 0.70 (0.43–1.12) | 0.134 | 1.17 (0.75–1.80) | 0.492 |
Divorced, widowed or single | -ref- | -ref- | -ref- | -ref- | -ref- | -ref- |
Comorbidity | ||||||
Myocardial infarction | 0.87 (0.28–2.76) | 0.817 | 0.39 (0.10–1.59) | 0.189 | 1.09 (0.34–3.49) | 0.890 |
Congestive heart disease | 0.84 (0.27–2.67) | 0.767 | 1.83 (0.53–6.26) | 0.337 | 1.64 (0.56–4.78) | 0.365 |
Hypertension | 0.67 (0.44–1.02) | 0.062 | 0.89 (0.57–1.40) | 0.613 | 0.63 (0.42–0.95) | 0.028 |
Peripheral vascular disease | 0.68 (0.37–1.24) | 0.208 | 0.70 (0.36–1.34) | 0.277 | 0.47 (0.25–0.88) | 0.017 |
Chronic pulmonary disease | 0.95 (0.44–2.05) | 0.896 | 0.96 (0.42–2.20) | 0.931 | 1.30 (0.63–2.68) | 0.478 |
Ulcer disease | 0.64 (0.22–1.88) | 0.418 | 0.39 (0.12–1.31) | 0.127 | 0.68 (0.24–1.95) | 0.469 |
Diabetes | 0.76 (0.39–1.46) | 0.404 | 0.60 (0.29–1.24) | 0.166 | 0.72 (0.38–1.37) | 0.317 |
Cancer Tumour | 0.64 (0.11–3.65) | 0.619 | 0.46 (0.05–4.69) | 0.514 | 1.48 (0.26–8.38) | 0.658 |
Cerebrovascular disease | 0.81 (0.24–2.74) | 0.729 | 0.49 (0.13–1.80) | 0.282 | 0.44 (0.11–1.73) | 0.240 |
Back pain (backache) | 0.74 (0.37–1.47) | 0.393 | 0.80 (0.38–1.70) | 0.562 | 0.79 (0.40–1.55) | 0.490 |
Rheumatologic disease | 0.40 (0.19–0.84) | 0.015 | 0.88 (0.40–1.93) | 0.742 | 0.63 (0.30–1.34) | 0.230 |
Depression | 0.50 (0.23–1.09) | 0.081 | 0.32 (0.13–0.75) | 0.009 | 0.15 (0.06–0.40) | < 0.001 |
Other pathologies | ||||||
Back | 1 (0.57–1.75) | 0.992 | 1.15 (0.63–2.08) | 0.647 | 0.82 (0.48–1.40) | 0.460 |
Homolateral hip | 0.62 (0.20–1.89) | 0.402 | 0.28 (0.08-1) | 0.050 | 0.53 (0.17–1.60) | 0.259 |
Contraletral hip | 1.01 (0.39–2.60) | 0.982 | 0.44 (0.15–1.25) | 0.122 | 0.68 (0.27–1.76) | 0.427 |
Contralateral knee | 0.87 (0.56–1.35) | 0.535 | 0.70 (0.44–1.12) | 0.134 | 1.05 (0.69–1.60) | 0.833 |
Upper limbs | 0.91 (0.33–2.51) | 0.859 | 1 (0.33–3.04) | 0.995 | 1.29 (0.49–3.40) | 0.606 |
OA severity (Ahlbäck scale) | ||||||
Mild or moderate | -ref- | -ref- | -ref- | -ref- | -ref- | -ref- |
Severe | 1.22 (0.70–2.14) | 0.485 | 1.84 (0.97–3.50) | 0.062 | 2.53 (1.35–4.73) | 0.004 |
Days in hospital | 0.98 (0.92–1.03) | 0.419 | 0.96 (0.90–1.03) | 0.252 | 0.96 (0.91–1.02) | 0.186 |
Postoperative complications | 1.31 (0.70–2.46) | 0.404 | 1.98 (0.99–3.95) | 0.054 | 1.50 (0.82–2.73) | 0.189 |
Readmissions (6 months) | 0.54 (0.30–0.98) | 0.042 | 0.58 (0.30–1.11) | 0.101 | 0.60 (0.32–1.12) | 0.110 |
Complications from hospital discharge | 0.35 (0.16–0.76) | 0.007 | 0.25 (0.11–0.59) | 0.002 | 0.51 (0.23–1.12) | 0.093 |
Rehabilitation from hospital discharge | 1.38 (0.86–2.22) | 0.181 | 1.64 (0.99–2.73) | 0.057 | 1.37 (0.87–2.16) | 0.174 |
Reintervention during the follow-up | 0.56 (0.28–1.11) | 0.095 | 0.49 (0.23–1.04) | 0.062 | 0.35 (0.16–0.79) | 0.011 |